9 results match your criteria: "Radboud Institute for Medical Innovations[Affiliation]"
Trial versus real world circumstances and how to interpret pharmacokinetic data.
Clin Infect Dis
December 2024
Radboud university medical center, department of pharmacy, Radboud Institute for Medical Innovations (RIMI), Nijmegen, the Netherlands.
Current opinion: antiretrovirals during pregnancy and breastfeeding.
Curr Opin HIV AIDS
November 2024
Department of Pharmacy, Radboud Institute for Medical Innovations (RIMI), Radboud University Medical Center, Nijmegen, The Netherlands.
Article Synopsis
- - The review focuses on recent findings over the last two years regarding how antiretroviral drugs behave in pregnant women, including their effects on placental transfer and exposure through breastmilk.
- - It highlights key developments like the FDA's label change for Bictegravir due to its decreased yet adequate concentration during pregnancy, as well as findings from studies on long-acting formulations like cabotegravir and rilpivirine.
- - The overall conclusion emphasizes the need for better drug data during pregnancy and lactation, suggesting that more research and incentives are necessary to ensure women receive accurate information about their medications early in the drug development process.
Concomitant use of anabolic androgen steroids and cabotegravir/rilpivirine leading to virological failure and development of two-class resistance.
AIDS
September 2024
Department of Internal Medicine.
Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.
J Antimicrob Chemother
September 2024
Research Department, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Background: We investigated the impact of Drug-Drug Interactions (DDIs) on virologic control among HIV-positive pregnant women initiating antiretroviral therapy while identifying drivers for Traditional Medicine (TM) use and exploring the nature and extent of TM-related DDIs.
Methods: Employing a three-pronged approach, we examined DDIs arising from comedication, including TM, in ART. The DolPHIN-2 trial (NCT03249181) randomized 268 HIV-positive pregnant women in Uganda and South Africa to dolutegravir (DTG)-based (135) or efavirenz-based (133) regimens while systematically recording comedications and screening for DDIs.
Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV.
Clin Infect Dis
December 2024
Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Medical Innovations (RIMI), Nijmegen, The Netherlands.
This case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70%-75% lower. No virologic failure or vertical transmission occurred.
View Article and Find Full Text PDFEvaluation of the drug-drug interaction between triazole antifungals and cystic fibrosis transmembrane conductance regulator modulators in a real-life cohort.
Med Mycol
March 2024
Department of Pulmonology and Adult CF Centre, Haga Teaching Hospital, The Hague, Netherlands.
Limited data on the clinical management of drug-drug interactions between triazoles and Cystic Fibrosis transmembrane conductance regulator (CFTR) modulators are available. We retrospectively evaluated azole target attainment and dose adaptations in patients from two Dutch CF centres concomitantly receiving triazoles and CFTR modulators. In total, 21 patients with 59 triazole trough concentrations were evaluated.
View Article and Find Full Text PDFComparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV.
AIDS
June 2024
Radboud University Medical Center, Department of Pharmacy, Radboud Institute for Medical Innovations (RIMI), Nijmegen, the Netherlands.
Article Synopsis
- Both dolutegravir and efavirenz are effective treatments for preventing HIV transmission during pregnancy but may cause neuropsychiatric symptoms, which need further investigation in this population.
- A secondary analysis of the DolPHIN2 study assessed depression, anxiety, and sleep quality in 268 women who received either treatment late in pregnancy, showing notable rates of depression but no differences between the drug regimens.
- Findings indicate high initial depression scores that decreased over time, emphasizing the importance of psychological support for women diagnosed with HIV during pregnancy.
High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints.
Clin Pharmacokinet
December 2023
Department of Pharmacy, Radboud university Medical Center, Radboud Institute for Medical Innovations, Geert Grooteplein-Zuid 10, Postbox 9101, 6500 HB, Nijmegen, The Netherlands.
Isavuconazole exposure-response relationships have been studied with a focus on total rather than unbound exposure, assuming a constant unbound fraction of 1%. We observed a median (range) unbound fraction of 1.59% (0.
View Article and Find Full Text PDFPopulation Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies.
Clin Pharmacokinet
December 2023
Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Medical Innovations, Postbox 9101, 6500 HB, Nijmegen, Geert Grooteplein Zuid 10, The Netherlands.
Background And Objectives: Isavuconazole is a broad-spectrum antifungal agent for the management of invasive fungal disease. Optimised drug exposure is critical for patient outcomes, specifically in the critically ill population. Solid information on isavuconazole pharmacokinetics including protein binding in patients in the intensive care unit is scarce.
View Article and Find Full Text PDF